Who are KPI-121 0.25% Ophthalmic Suspension's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kpi-121-0-25-ophthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

KPI-121 0.25% Ophthalmic Suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KPI-121 0.25% Ophthalmic Suspension (KPI-121 0.25% Ophthalmic Suspension) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic anti-inflammatory suspension. Area: Ophthalmology.

phase 3 Ophthalmic anti-inflammatory suspension Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

KPI-121 0.25% Ophthalmic Suspension (KPI-121 0.25% Ophthalmic Suspension) — Kala Pharmaceuticals, Inc.. KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
KPI-121 0.25% Ophthalmic Suspension TARGET	KPI-121 0.25% Ophthalmic Suspension	Kala Pharmaceuticals, Inc.	phase 3	Ophthalmic anti-inflammatory suspension

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic anti-inflammatory suspension class)

Kala Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KPI-121 0.25% Ophthalmic Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/kpi-121-0-25-ophthalmic-suspension. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab